Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half‐life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers

• Published in: Alimentary pharmacology & therapeutics 2004-03, Vol.19 (6), p.655-662
• Main Authors: Galmiche, J. P., Bruley Des Varannes, S., Ducrotté, P., Sacher‐Huvelin, S., Vavasseur, F., Taccoen, A., Fiorentini, P., Homerin, M.
• Format: Article
• Language: English
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents - pharmacology; Biological and medical sciences; Cross-Over Studies; Digestive system; Esomeprazole - pharmacology; Gastric Acid; Gastroenterology. Liver. Pancreas. Abdomen; Half-Life; Humans; Hydrogen-Ion Concentration - drug effects; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Male; Medical sciences; Pharmacology. Drug treatments; Proton Pump Inhibitors; Pyridines - pharmacokinetics; Pyridines - pharmacology
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2004.01893.x

Summary Background : Proton pump inhibitors control gastric acidity better during the day than at night, when nocturnal acid breakthrough can occur. Tenatoprazole is a novel proton pump inhibitor with a seven‐fold longer plasma half‐life. Aim : To compare the effects of tenatoprazole 20 mg (T20), tenatoprazole 40 mg (T40) and esomeprazole 40 mg (E40) on intragastric acidity in healthy volunteers. Methods : This randomized, three‐period, cross‐over study enrolled 18 Helicobacter pylori‐negative volunteers, who received E40, T20 and T40 once daily for 7 days with a 14‐day washout between periods. Twenty‐four‐hour gastric pH monitoring was performed on day 7. Serum gastrin was assessed on day 8. Results : T40 induced a more potent acid inhibition than T20 (24‐h median pH: 4.6 vs. 4.0, P